Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. MediciNova Inc. (MNOV) Message Board

MediciNova (Nasdaq:MNOV) Gets New Patent Covering MN-221 in Irritable

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | | Next


Post# of 68
Posted On: 11/12/2013 1:21:30 AM
Posted By: karnacua2

http://pennyomega.com/img/anfi1.jpg Amira Nature Foods Ltd. (NYSE:ANFI)


ANFI reported strong financial results, reflecting its ability to consistently add new customers in India and internationally, enter new markets as well as the continued growing demand for its premium product offerings.


On its second quarter fiscal 2014, ANFI posted revenue of $108.0 million, a 36.1% increase year over year, and profit after tax of $6.3 million, a 90% increase compared to $3.3 million in the same period the prior year.


ANFI reiterates its previously issued guidance and continues to expect full year fiscal 2014 revenue in the range of $480 million to $507 million and EBITDA in the range of $62 million to $66 million (based on foreign exchange rates as of September 30, 2013). This is in line with long-term guidance previously provided to the investment community in connection with ANFI ’s initial public offering.


Shares of ANFI closed at $14.80 on Monday's trading session.


http://pennyomega.com/img/anfi_chart1.png


ANFI sells Basmati rice, a premium long-grain rice grown only in certain regions of the Indian sub-continent, under their flagship Amira brand as well as under other third party brands. ANFI sells its products primarily in emerging markets through a broad distribution network.


More about Amira Nature Foods Ltd. (NYSE:ANFI) at www.amirafoods.com .


**


http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)


CRWE has updated its membership driven online e-commerce venture business plan. The name of the business will be known as “iB2B Global”.


Looking to deliver value for its stockholders in both the near and long term, CRWE is targeting the multi-billion dollar B2B Industry with its iB2B Global project. While the sheer number of retail transactions throughout the globe on a daily basis is of course larger, the money flow created in B2B is formidable due to the size of the transactions.


CRWE ‘s iB2B Global mission is to make it easy for anyone to buy or sell anywhere in the world.


http://pennyomega.com/img/crwenov11.png


As a worldwide online multi-media publisher, CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. The company launches, invests and manages select businesses, projects and real estate endeavors.


More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .


**


http://pennyomega.com/img/mnov.jpg MediciNova, Inc. (Nasdaq:MNOV)


Irritable bowel syndrome is a functional gastrointestinal disorder; it causes cramping, abdominal pain, bloating gas, diarrhea and constipation.


Irritable bowel syndrome is estimated to affect 10 to 15 percent of the population.


MNOV reported that a new U.S. patent has been granted which covers MN-221 in the treatment of irritable bowel syndrome.


The new patent (U.S. Patent No. 8,518,995) will expire no earlier than April 2031. The claims cover a method for treatment of irritable bowel syndrome using certain compounds including MN-221. The claims cover various routes of administration including oral, injectable and transdermal.


MNOV stock closed at $2.17, representing an increase of $0.02 (or +0.93%).


http://pennyomega.com/img/mnov_chart.png


MNOV is a biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market.


More about MediciNova, Inc. (Nasdaq:MNOV) at www.medicinova.com .


**


Read Full Disclaimer at www.drstockpick.com/disclaimer



(0)
(0)




MediciNova Inc. (MNOV) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us